Is CTVA Stock Worth Buying After a Powerful Rally and Earnings Beat?

CTVA’s Earnings Momentum Supports the Bull Case

Corteva reported first-quarter 2026 operating earnings of $1.50 per share, up 32.7% year over year. The result topped the consensus mark by 27.1%, signaling that stronger Seed execution and Crop Protection volume growth are translating into earnings leverage.

Net sales rose 11% to $4.91 billion and beat expectations by 5.6%. Organic sales increased 7%, with volumes up across all regions and currency adding four percentage points to reported growth.

Margins also improved. Operating EBITDA advanced 21% to $1.44 billion, while the margin expanded roughly 240 basis points to more than 29%, helped by organic growth, productivity actions, lower input costs and favorable currency movements.

Corteva’s Valuation Leaves Less Room for Error

The rally has pushed valuation above several benchmarks. CTVA trades at 22.52X forward 12-month earnings, compared with 15.68X for the Zacks sub-industry, 17.28X for the Zacks sector and 20.11X for the S&P 500.

Image Source: Zacks Investment Research

The multiple is also above Corteva’s five-year median of 19.04X, though below the five-year high of 23.93X. That premium does not invalidate the earnings story, but it makes continued execution more important.

Bayer AG BAYRY remains a relevant comparison because its crop science operations also span seeds, traits and crop protection. FMC Corporation FMC offers another reference point for investors watching crop protection demand, pricing and innovation cycles.

CTVA’s Separation Creates Near-Term Cash Costs

Corteva remains on track to separate its Seed and Crop Protection businesses in the fourth quarter of 2026. The future advanced seed and genetics company will be named Vylor, while the Crop Protection business will retain the Corteva name.

Image Source: Zacks Investment Research

The transition carries cash costs. One-time separation costs are expected to total roughly $350 million, with most spending anticipated in the second half of 2026. Corteva has also included $50 million of net dis-synergies in its 2026 guidance.

The board approved an approximately $1.5 billion pretax contribution to the U.S. pension plan. That move is intended to support investment-grade credit profiles for both companies, but it could weigh on reported cash flow this year.

Corteva’s Pipeline Adds Long-Term Upside

Corteva’s innovation pipeline gives the bull case a longer runway. New Crop Protection products are expected to approach $2 billion in revenues in 2026, with Arylex and Rinskor still below peak sales potential.

The Seed pipeline adds another layer. Corteva plans to launch proprietary hybrid wheat in 2027, tied to an estimated $1 billion long-term opportunity, while next-generation traits are targeted around the start of the next decade.

The Bayer licensing agreement is expected to generate roughly $1 billion in incremental revenues over the next decade. These platforms could extend growth beyond the current agricultural cycle, although product development, adoption and commercialization carry execution risk.

CTVA’s Buy Rank Favors Momentum Over Value

The bottom line is that CTVA looks better suited for investors prioritizing earnings momentum than those looking for a discounted valuation. The operating backdrop has improved, but the stock’s premium multiple and separation-related cash burden raise the bar for delivery.

CTVA currently carries a Zacks Rank #2 (Buy). That rank supports a favorable near-term earnings view, reinforced by a 1.3% upward move in the current fiscal year earnings estimate over the past four weeks and a Momentum Score of A. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Style Scores are less supportive outside momentum. CTVA has a Value Score of D, Growth Score of D and VGM Score of D, indicating that the stock’s appeal is not broad-based across valuation and growth factors.

For now, investor interest remains justified by earnings delivery, estimate revision momentum and a clear innovation pipeline. The case is positive, but it depends more on execution than on valuation support.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research